|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Study Type: | Interventional |
|---|---|
| Study Design: | Allocation: Randomized; Endpoint Classification: Efficacy Study; Intervention Model: Crossover Assignment; Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor); Primary Purpose: Treatment |
| Conditions: |
Attention Deficit Hyperactivity Disorder Reading Disorder |
| Interventions: |
Drug: Atomoxetine Hydrochloride Drug: placebo |
Participant Flow
| Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations |
|---|
| No text entered. |
| Significant events and approaches for the overall study following participant enrollment, but prior to group assignment |
|---|
| Period I: screening/washout (89 patients screened, 13 screen-failures;45 controls screened). Period II (Visits 2-5): patients received treatment for 4 weeks and then underwent 2-week washout period after which they crossed over to receive the alternate treatment for 4 additional weeks. Period III (Visits 6-12): optional open-label (1 country only). |
| Description | |
|---|---|
| Atomoxetine First, Then Placebo | Atomoxetine 1.2 mg/kg/day, by mouth for 4 weeks, 2 week washout period and then cross-over to placebo, every day, by mouth for 4 weeks. |
| Placebo First, Then Atomoxetine | Placebo every day, by mouth for 4 weeks, 2 week washout period and then cross-over to atomoxetine 1.2 mg/kg/day, by mouth for 4 weeks. |
| Normal Control | Untreated normal controls were children selected from the general population. The normal control was matched (have same proportion) by sex (male/female) and by age (have same age range) as the study population. |
| Reading Disordered Control | Untreated reading disordered control group was comprised of children with reading disorder who received standard remedial teaching therapy. |
| Atomoxetine First, Then Placebo | Placebo First, Then Atomoxetine | Normal Control | Reading Disordered Control | |
|---|---|---|---|---|
| STARTED | 39 | 37 | 27 | 18 |
| COMPLETED | 39 | 32 | 26 | 18 |
| NOT COMPLETED | 0 | 5 | 1 | 0 |
| Adverse Event | 0 | 1 | 0 | 0 |
| Withdrawal by Subject | 0 | 3 | 0 | 0 |
| Parent/Caregiver Decision | 0 | 1 | 0 | 0 |
| Entry Criteria Exclusion | 0 | 0 | 1 | 0 |
| Atomoxetine First, Then Placebo | Placebo First, Then Atomoxetine | Normal Control | Reading Disordered Control | |
|---|---|---|---|---|
| STARTED | 14 [1] | 11 [1] | 0 | 0 |
| COMPLETED | 9 | 7 | 0 | 0 |
| NOT COMPLETED | 5 | 4 | 0 | 0 |
| Adverse Event | 1 | 0 | 0 | 0 |
| Lost to Follow-up | 0 | 1 | 0 | 0 |
| Parent/Caregiver Decision | 1 | 0 | 0 | 0 |
| Lack of Efficacy | 3 | 3 | 0 | 0 |
| [1] | These are patients who continued in optional open-label period (1 country). All received atomoxetine |
|---|
Baseline Characteristics
| Description | |
|---|---|
| Atomoxetine First, Then Placebo | Atomoxetine 1.2 mg/kg/day for 4 weeks, 2 week washout, and then placebo for 4 weeks |
| Placebo First, Then Atomoxetine | Placebo for 4 weeks, 2 week washout, and then atomoxetine 1.2 mg/kg/day for 4 weeks. |
| Normal Control | Untreated normal controls were children selected from the general population. The normal control was matched (have same proportion) by sex (male/female) and by age (have same age range) as the study population. |
| Reading Disordered Control | Untreated reading disordered control group was comprised of children with reading disorder who received standard remedial teaching therapy. |
| Atomoxetine First, Then Placebo | Placebo First, Then Atomoxetine | Normal Control | Reading Disordered Control | Total | |
|---|---|---|---|---|---|
|
Number of Participants
[units: participants] |
39 | 37 | 27 | 18 | 121 |
|
Age
[units: years] Mean ± Standard Deviation |
10.0 ± 1.34 | 9.9 ± 1.25 | 9.9 ± 1.01 | 10.6 ± 0.99 | 10.0 ± 1.2 |
|
Gender
[units: participants] |
|||||
| Female | 13 | 10 | 10 | 5 | 38 |
| Male | 26 | 27 | 17 | 13 | 83 |
|
Region of Enrollment
[units: participants] |
|||||
| Belgium | 18 | 15 | 0 | 16 | 49 |
| Netherlands | 21 | 22 | 27 | 2 | 72 |
|
Study Arm - Diagnosis
[units: participants] |
|||||
| ADHD-Combined Type | 13 | 15 | 0 | 0 | 28 |
| Reading Disorder | 11 | 12 | 0 | 18 | 41 |
| ADHD-Combined Type + Reading Disorder | 15 | 10 | 0 | 0 | 25 |
| No Disorder | 0 | 0 | 27 | 0 | 27 |
Outcome Measures
| 1. Primary: | Stop Signal Reaction Time (SSRT) as Derived From the Stop Signal Reaction Time Paradigm [ Time Frame: Baseline and Week 4 of initial therapy and Week 4 of crossover therapy ] |
| 2. Secondary: | Change From Baseline in Mean Stop Signal Reaction Time Comparison of ADHD-C to Normal Control Group in >=10 Year Old Subset [ Time Frame: Baseline and 4 weeks of therapy ] |
| 3. Secondary: | Change From Baseline in Mean Stop Signal Reaction Time Comparison of ADHD-C+RD and RD to Reading Disordered Control Group in >=10 Year Old Subset [ Time Frame: Baseline and 4 weeks of therapy ] |
| 4. Secondary: | Lexical Decision Task Mean Reaction Time: Correct Words [ Time Frame: Baseline and Week 4 of initial therapy and Week 4 of crossover therapy ] |
| 5. Secondary: | Lexical Decision Task Mean Reaction Time: Pseudo Words [ Time Frame: Baseline and Week 4 of initial therapy and Week 4 of crossover therapy ] |
| 6. Secondary: | Working Memory by Corsi Block Tapping Test (CBTT) [ Time Frame: Baseline and Week 4 of initial therapy and Week 4 of crossover therapy ] |
| 7. Secondary: | Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator-Administered and Scored - Total Score [ Time Frame: Baseline and Week 4 of initial therapy and Week 4 of crossover therapy ] |
| 8. Secondary: | Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator-Administered and Scored - Inattention Subscale [ Time Frame: Baseline and Week 4 of initial therapy and Week 4 of crossover therapy ] |
| 9. Secondary: | Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator-Administered and Scored - Hyperactivity-Impulsivity Subscale [ Time Frame: Baseline and Week 4 of initial therapy and Week 4 of crossover therapy ] |
| 10. Secondary: | Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator-Administered and Scored - Total T-Score [ Time Frame: Baseline and Week 4 of initial therapy and Week 4 of crossover therapy ] |
| 11. Secondary: | Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Improvement Scale [ Time Frame: 4 week therapy endpoint ] |
| 12. Secondary: | Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Severity Scale [ Time Frame: 4 week therapy endpoint ] |
| 13. Secondary: | Change From Baseline in Phonological Task Mean Reaction Time Comparison of ADHD-C to Normal Control Group in >=10 Year Old Subset: Pseudohomophones [ Time Frame: Baseline and 4 weeks of therapy ] |
| 14. Secondary: | Change From Baseline in Phonological Task Mean Reaction Time Comparison of ADHD-C to Normal Control Group in >=10 Year Old Subset: Pseudo Words [ Time Frame: Baseline and 4 weeks of therapy ] |
| 15. Secondary: | Change From Baseline in Phonological Task Mean Reaction Time Comparison of ADHD-C+RD and RD to Reading Disordered Control Group in >=10 Year Old Subset: Pseudohomophones [ Time Frame: Baseline and 4 weeks of therapy ] |
| 16. Secondary: | Change From Baseline in Phonological Task Mean Reaction Time Comparison of ADHD-C+RD and RD to Reading Disordered Control Group in >=10 Year Old Subset: Pseudo Words [ Time Frame: Baseline and 4 weeks of therapy ] |
More Information
| Principal Investigators are NOT employed by the organization sponsoring the study. | ||||||
| There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. | ||||||
The agreement is:
|
| Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data |
|---|
| No text entered. |
| Responsible Party: | Chief Medical Officer, Eli Lilly |
| ClinicalTrials.gov Identifier: | NCT00191906 History of Changes |
| Other Study ID Numbers: | 7955, B4Z-MC-LYCK |
| Study First Received: | September 12, 2005 |
| Results First Received: | December 11, 2008 |
| Last Updated: | May 17, 2010 |
| Health Authority: | Belgium: Directorate general for the protection of Public health: Medicines; Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) |